{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T10:10:46Z","timestamp":1753870246947,"version":"3.41.2"},"reference-count":132,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Reviews in Medical Virology"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Congenital CMV, enteroviruses, human parechovirus and herpes simplex virus are all common causes of severe central nervous system (CNS) infection in neonates. The introduction of screening (i.e. newborn hearing screening programme), integration of molecular syndromic testing (i.e. multiplex polymerase chain reaction assays) and increase in sexually transmitted infections (i.e. anogenital herpes) have contributed to increases in each of these infections over the last decade. However, therapeutic options are highly limited in part due to the lack of epidemiological data informing trials. This review will describe our current understanding of the clinical burden and epidemiology of these severe neonatal CNS infections, outline the novel antiviral and vaccines in the pipeline and suggest future research studies which could help develop new therapeutics.<\/jats:p>","DOI":"10.1002\/rmv.2421","type":"journal-article","created":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T04:19:04Z","timestamp":1673669944000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Management of neonatal central nervous system viral infections: Knowledge gaps and research priorities"],"prefix":"10.1002","volume":"33","author":[{"given":"Movin","family":"Abeywickrema","sequence":"first","affiliation":[{"name":"Department of Infection Guy's and St Thomas' NHS Foundation Trust  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominic","family":"Kelly","sequence":"additional","affiliation":[{"name":"Oxford Vaccine Group Department of Paediatrics University of Oxford and the NIHR Oxford Biomedical Research Centre  Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seilesh","family":"Kadambari","sequence":"additional","affiliation":[{"name":"Department of Paediatric Infectious Diseases Great Ormond Street Hospital for Children NHS Foundation Trust  London UK"},{"name":"University College London Great Ormond Street Institute of Child Health  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473\u20103099(1930416\u20105)"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild\u20102018\u2010315643"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu381"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0b013e31821b178f"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/v13050816"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.535"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0804749"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/pch\/pxaa083"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1404599"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild\u20102018\u2010316010"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2034"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13224\u2010014\u20100615\u20103"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13052\u2010017\u20100358\u20108"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001527"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2019.06.009"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0194186"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2015.08.003"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(20)31868\u20107"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310214"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0022\u20103476(03)00192\u20106"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2009.08.012"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.40.9.2202"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1086\/528376"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/antib9040060"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/20.5.1201"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2015.01.013"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw172.20"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2012\u20101136"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000012930"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.108.2.230"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2019.12.056"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199102143240703"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000435509.75114.3d"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003509"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.1.150\u2010157.2001"},{"key":"e_1_2_8_37_1","unstructured":"National Institute of Allergy and Infectious Diseases (NIAID).A phase II single stage single\u2010arm investigation of oral valganciclovir therapy in infants with asymptomatic congenital cytomegalovirus infection. clinicaltrials.gov.2020. Accessed December 6 2020.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03301415"},{"key":"e_1_2_8_38_1","unstructured":"Cytomegalovirus. Accessed January 26 2021.https:\/\/legacyscreening.phe.org.uk\/cytomegalovirus"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.2165\/11316080\u2010000000000\u201000000"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/pix011"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000353"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/14767050410001701349"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365540600786598"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir138"},{"key":"e_1_2_8_45_1","unstructured":"Hookipa Biotech GmbH.A randomized placebo\u2010control phase 2 study of HB\u2010101 a bivalent cytomegalovirus (CMV) vaccine in CMV\u2010seronegative recipient (R\u2010) patients awaiting kidney transplantation from living CMV\u2010seropositive donors (D+). clinicaltrials.gov.2020. Accessed December 30 2020.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03629080"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.01.029"},{"key":"e_1_2_8_47_1","unstructured":"ModernaTX Inc.A phase 1 randomized observer\u2010blind placebo\u2010controlled dose\u2010ranging study to evaluate the safety reactogenicity and immunogenicity of cytomegalovirus vaccines mRNA\u20101647 and mRNA\u20101443 when administered to healthy adults. clinicaltrials.gov.2019. Accessed December 7 2020.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03382405"},{"key":"e_1_2_8_48_1","unstructured":"ModernaTX Inc.A phase 2 randomized observer\u2010blind placebo\u2010controlled dose\u2010finding trial to evaluate the safety and immunogenicity of cytomegalovirus vaccine mRNA\u20101647 in healthy adults. clinicaltrials.gov.2020. Accessed December 7 2020.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04232280"},{"key":"e_1_2_8_49_1","unstructured":"Moderna completes enrollment of cytomegalovirus (CMV) vaccine (mRNA\u20101647) phase 2 study | Moderna Inc. Accessed February 23 2021.https:\/\/investors.modernatx.com\/news\u2010releases\/news\u2010release\u2010details\/moderna\u2010completes\u2010enrollment\u2010cytomegalovirus\u2010cmv\u2010vaccine\u2010mrna\/"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw365"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz141"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.09.067"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz447"},{"key":"e_1_2_8_54_1","unstructured":"Multi\u2010antigen CMV\u2010modified vaccinia ankara vaccine in treating pediatric patients with positive cytomegalovirus undergoing donor stem cell transplant \u2010 full text view \u2010 ClinicalTrials.gov. Accessed December 8 2020.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03354728"},{"key":"e_1_2_8_55_1","unstructured":"City of Hope Medical Center.A phase II randomized placebo\u2010controlled multicenter trial to evaluate protective function of an optimized dose of CMVPepVax in recipients of an allogeneic hematopoietic stem cell transplant. clinicaltrials.gov.2019. Accessed December 30 2020.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02396134"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1177\/000992289603500602"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/jpc.13083"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065954"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007\u20103799"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/ped.13658"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02106\u201020"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12929\u2010019\u20100573\u20102"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2021.10.002"},{"key":"e_1_2_8_64_1","unstructured":"ChimerixA.Multicenter open\u2010label study of CMX001 treatment of serious diseases or conditions caused by dsDNA viruses. clinicaltrials.gov.2020. Accessed November 17 2020.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01143181"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v99.4.1159"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00717\u201019"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0192602"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.3390\/v11050414"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2019.01.021"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2012.12.029"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41579\u2010018\u20100005\u20104"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piv015"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b01414"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1177\/2324709617729393"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr\u20102017\u2010224133"},{"key":"e_1_2_8_76_1","unstructured":"Study to evaluate the tolerance and pharmacokinetics of suramin sodium \u2010 full text view \u2010 ClinicalTrials.gov. Accessed December 13 2020.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03804749"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2014.60"},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104781"},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1565266"},{"key":"e_1_2_8_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2018.11.001"},{"key":"e_1_2_8_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2014.12.054"},{"key":"e_1_2_8_82_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01429\u201015"},{"key":"e_1_2_8_83_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.18189"},{"key":"e_1_2_8_84_1","unstructured":"AiCuris Anti\u2010infective Cures GmbH.A randomized open label multi\u2010center comparative trial to assess the efficacy and safety of pritelivir versus foscarnet for the treatment of acyclovir\u2010resistant mucocutaneous HSV (herpes simplex virus) infections in immunocompromised adults (PRIOH\u20101). clinicaltrials.gov.2020. Accessed December 30 2020.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03073967"},{"key":"e_1_2_8_85_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis019"},{"key":"e_1_2_8_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346\u20108138.13948"},{"key":"e_1_2_8_87_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep23146"},{"key":"e_1_2_8_88_1","doi-asserted-by":"publisher","DOI":"10.1177\/1753425914537921"},{"key":"e_1_2_8_89_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000059765.92623.70"},{"key":"e_1_2_8_90_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000497"},{"key":"e_1_2_8_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2018.10.002"},{"key":"e_1_2_8_92_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006670"},{"key":"e_1_2_8_93_1","unstructured":"Immunization in the Asia\u2010Pacific region \u2010 ScienceDirect. Accessed June 18 2022.https:\/\/www.sciencedirect.com\/science\/article\/pii\/B9781455700905000690"},{"key":"e_1_2_8_94_1","unstructured":"LiQ.The safety immune persistence and consistency of inactivated enterovirus 71 vaccine (human diploid cell KMB\u201017). clinicaltrials.gov.2018. Accessed June 22 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02999828"},{"key":"e_1_2_8_95_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2018.1430572"},{"key":"e_1_2_8_96_1","unstructured":"HK inno.N Corporation.A randomized double\u2010blind placebo\u2010controlled phase 1 clinical trial to investigate the safety and immunogenicity of high\u2010dose IN\u2010B001 after administration in healthy subjects. clinicaltrials.gov.2020. Accessed December 10 2020.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04637919"},{"key":"e_1_2_8_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.06.023"},{"key":"e_1_2_8_98_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1303224"},{"key":"e_1_2_8_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.09.072"},{"key":"e_1_2_8_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.03.065"},{"key":"e_1_2_8_101_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja18.00149"},{"key":"e_1_2_8_102_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010019\u201045445\u2010z"},{"key":"e_1_2_8_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473\u20103099(18)30288\u20103"},{"key":"e_1_2_8_104_1","doi-asserted-by":"publisher","DOI":"10.1086\/649863"},{"key":"e_1_2_8_105_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015\u20102848"},{"key":"e_1_2_8_106_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2083"},{"key":"e_1_2_8_107_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002052"},{"key":"e_1_2_8_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214\u2010109X(16)30362\u2010X"},{"key":"e_1_2_8_109_1","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild\u20102013\u2010303762"},{"volume-title":"StatPearls","year":"2020","author":"Fernandes ND","key":"e_1_2_8_110_1"},{"key":"e_1_2_8_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2006.07.051"},{"key":"e_1_2_8_112_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268820002629"},{"key":"e_1_2_8_113_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471\u20102334\u201011\u2010155"},{"key":"e_1_2_8_114_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20103016.1996.tb00070.x"},{"key":"e_1_2_8_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2014.05.012"},{"volume-title":"Sexually Transmitted Infections (STIs): Annual Data Tables","key":"e_1_2_8_116_1"},{"key":"e_1_2_8_117_1","unstructured":"SamiesN.Evaluation of the pharmacokinetics and pharmacodynamics of valacyclovir in neonates with neonatal herpes simplex virus disease who have completed standard of care treatment with acyclovir. clinicaltrials.gov.2020. Accessed December 21 2020.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04448392"},{"key":"e_1_2_8_118_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2012\u20103216"},{"key":"e_1_2_8_119_1","unstructured":"BASHH Guidelines. Accessed January 16 2021.https:\/\/www.bashhguidelines.org\/current\u2010guidelines\/genital\u2010ulceration\/anogenital\u2010herpes\u20102014\/"},{"key":"e_1_2_8_120_1","doi-asserted-by":"publisher","DOI":"10.5863\/1551\u20106776\u201019.2.72"},{"key":"e_1_2_8_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2016.08.024"},{"key":"e_1_2_8_122_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12582"},{"key":"e_1_2_8_123_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12977"},{"key":"e_1_2_8_124_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23073431"},{"key":"e_1_2_8_125_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2054"},{"key":"e_1_2_8_126_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103151"},{"key":"e_1_2_8_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104755"},{"key":"e_1_2_8_128_1","doi-asserted-by":"publisher","DOI":"10.1111\/1348\u20100421.12482"},{"key":"e_1_2_8_129_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.12.018"},{"key":"e_1_2_8_130_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.11.042"},{"key":"e_1_2_8_131_1","unstructured":"An HSV\u20102 trivalent vaccine is immunogenic in rhesus macaques and highly efficacious in Guinea pigs. Accessed November 18 2020.https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5245903\/"},{"key":"e_1_2_8_132_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040206616671571"},{"key":"e_1_2_8_133_1","unstructured":"The promise of mRNA vaccines: a biotech and industrial perspective | npj Vaccines. Accessed June 24 2022.https:\/\/www.nature.com\/articles\/s41541\u2010020\u20100159\u20108"}],"container-title":["Reviews in Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rmv.2421","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/rmv.2421","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rmv.2421","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T05:35:40Z","timestamp":1711690540000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/rmv.2421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":132,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1002\/rmv.2421"],"URL":"https:\/\/doi.org\/10.1002\/rmv.2421","archive":["Portico"],"relation":{},"ISSN":["1052-9276","1099-1654"],"issn-type":[{"type":"print","value":"1052-9276"},{"type":"electronic","value":"1099-1654"}],"subject":[],"published":{"date-parts":[[2023,1,13]]},"assertion":[{"value":"2022-07-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2421"}}